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Background: Pancreatic cancer is a leading cause of cancer-related deaths in the world with a 5-year survival rate of
less than 6%. Currently, there is no successful therapeutic strategy for advanced pancreatic cancer, and new effective
strategies are urgently needed. Recently, an arginine deprivation agent, arginine deiminase, was found to inhibit the
growth of some tumor cells (i.e., hepatocellular carcinoma, melanoma, and lung cancer) deficient in argininosuccinate
synthetase (ASS), an enzyme used to synthesize arginine. The purpose of this study was to evaluate the therapeutic
efficacy of arginine deiminase in combination with gemcitabine, the first line chemotherapeutic drug for patients
with pancreatic cancer, and to identify the mechanisms associated with its anticancer effects.
Methods: In this study, we first analyzed the expression levels of ASS in pancreatic cancer cell lines and tumor tissues
using immunohistochemistry and RT-PCR. We further tested the effects of the combination regimen of arginine
deiminase with gemcitabine on pancreatic cancer cell lines in vitro and in vivo.
Results: Clinical investigation showed that pancreatic cancers with reduced ASS expression were associated with
higher survivin expression and more lymph node metastasis and local invasion. Treatment of ASS-deficient PANC-1 cells
with arginine deiminase decreased their proliferation in a dose- and time-dependent manner. Furthermore, arginine
deiminase potentiated the antitumor effects of gemcitabine on PANC-1 cells via multiple mechanisms including
induction of cell cycle arrest in the S phase, upregulation of the expression of caspase-3 and 9, and inhibition
of activation of the NF-κB survival pathway by blocking NF-κB p65 signaling via suppressing the nuclear translocation
and phosphorylation (serine 536) of NF-κB p65 in vitro. Moreover, arginine deiminase can enhance antitumor activity of
gemcitabine-based chemotherapy in the mouse xenograft model.
Conclusions: Our results suggest that arginine deprivation by arginine deiminase, in combination with gemcitabine, may
offer a novel effective treatment strategy for patients with pancreatic cancer and potentially improve the outcome of
patients with pancreatic cancer.Background
Pancreatic cancer is the fourth most common cause of
cancer-related deaths in western countries, with a me-
dian overall survival of less than 6 months and a 5-year
survival rate of less than 6% [1,2]. In 2014, it is estimated* Correspondence: qyma56@mail.xjtu.edu.cn
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pancreatic cancer and 39,590 will die of the disease [2].
Because of aggressive growth, early local invasion, and
tumor metastasis, the majority of patients (over 80%)
are diagnosed at an unresectable stage [3]. Gemcita-
bine (2'-Deoxy-2', 2'-difluorocytidine; GEM)-based chemo-
therapy has been used as a palliative cancer treatment for
more than two decades and is currently the first-line che-
motherapeutic agent for treatment of patients withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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atic cancer is highly resistant to chemotherapeutic agents,
a number of clinical trials show that GEM alone or in
combination with other regimens such as cetuximab, or
S-1 [an oral fluorourail (FU) derivative], does not improve
the overall survival of pancreatic cancer patients [4-6].
Therefore, it is imperative to develop novel therapeutic
strategies.
Arginine can be synthesized from citrulline by the en-
zymes of the urea cycle, namely argininosuccinate syn-
thetase (ASS) and argininosuccinate lyase (ASL), and is,
therefore, regarded as a nonessential amino acid for
humans and mice [7]. Some human cancers, such as
melanoma, lung cancer, renal cell carcinomas, and hepa-
tocellular carcinomas [8-10] do not express ASS and are
highly sensitive to arginine deprivation via arginine deimi-
nase (ADI). ADI is an arginine deprivation agent capable
of degrading arginine into citrulline [11,12]. ADI elimi-
nates intracellular arginine by reducing the extracellular
and plasma levels, thereby producing an arginine shortage
in the ASS-deficient tumor cells, but not affecting cells
that express ASS [10,13,14]. A recent study demonstrated
that several pancreatic cancer cells exhibit reduced ASS
expression, and the growth of these cells in vitro and
in vivo is inhibited via arginine elimination using a poly-
ethylene glycol-modified ADI (PEG-ADI) [15].
GEM, a pyrimidine-based antimetabolite, has been
used for the treatment of pancreatic cancer for two de-
cades [16,17]. It has been demonstrated that GEM acti-
vates the S-phase checkpoint via inhibition of DNA
replication [18]. As documented above, pancreatic can-
cers are often resistant to GEM through several mo-
lecular mechanisms [19-24]. NF-κB plays a critical role
in activating transcriptional events that lead to cell
survival, and activation of this signaling pathway is as-
sociated with GEM chemoresistance in pancreatic can-
cer cells [23,25,26]. Agents that block NF-κB activation
could reduce chemoresistance to GEM and may be
used in combination with GEM as a novel therapeutic
regimen for treating pancreatic cancer [27-30]. Previous
research has demonstrated that arginine deprivation ther-
apy and the associated agent ADI may be a promising
therapy for pancreatic cancer [15]. However, whether ADI
potentiates the anticancer activities of GEM in pancreatic
cancer cells and its precise mechanisms are not clear.
In this study, we aimed to examine the effects and
mechanisms of ADI alone and in combination with GEM
on the survival of pancreatic cancer cells in vitro and
in vivo in order to develop a novel effective therapeutic
strategy for treating pancreatic cancer. Our results show
that pancreatic cancer cells lacking ASS expression have
high sensitivity to arginine deprivation by ADI. Further,
when ADI was combined with GEM in ASS-negative pan-
creatic cancer cells, NF-κB signaling was suppressed andmore cell death was induced in vitro and in vivo. Clinic-
ally, pancreatic cancer patients with reduced ASS expres-
sion may have shorter survival times.
Methods
Reagents and chemicals
Diamidino-2-phenylindole (DAPI), crystal violet, Dimethyl
Sulfoxide (DMSO), methyl thiazolyl tetrazolium (MTT),
propidium iodide (PI), and RNase were obtained from
Sigma Chemical (St. Louis, MO, USA). Bicinchoninic acid
(BCA) protein assay reagent was from Pierce Chemical
(Rockford, IL, USA). The ADI gene was cloned from the
M. arginini genomic DNA, and the 46 kDa ADI recom-
binant protein (Additional file 1: Figure S1) was produced
as previously described [31]. ADI activity was deter-
mined by measuring the formation of L-citrulline from
L-arginine following a modified method using diacetyl
monoxime thiosemicarbazide [32]. One unit of ADI ac-
tivity is defined as the amount of enzyme catalyzing 1
μmol of L-arginine to 1 μmol of L-citrulline per min
under the assay conditions. Finally, the measured ac-
tivity of the ADI was 30 U per mg protein. GEM was pur-
chased from Eli Lilly France SA (Fergersheim, France).
Cell lines and cell culture
Human primary pancreatic cancer cell lines MIA PaCa-2,
PANC-1, and BxPC-3, and spleen metastatic pancreatic
cancer cell line SW1990, breast cancer cell lines MDA-
MB-453, BT474, MDA-MB-231, and MCF-7, and he-
patocellular carcinoma (HCC) cell lines HepG2 and
MHCC97-H were all purchased from the American
Type Culture Collection (ATCC). All cell lines were
maintained in the recommended medium (HyClone,
Logan, USA) containing 10% heat-inactivated fetal bo-
vine serum (HyClone) and 1% penicillin/streptomycin
(HyClone) in a humidified (37°C, 5% CO2) incubator.
Plastic wares for cell culture were obtained from BD
Bioscience (Franklin Lakes, NJ).
Tissue samples and immunohistochemistry
Thirty-seven paraffin-embedded pancreatic cancer tissues
were obtained from the First Affiliated Hospital of Med-
ical College, Xi’an Jiaotong University, between 2007 and
2010. The paraffin-embedded tissue samples were then
sliced into consecutive 4-μm-thick sections and prepared
for immunohistochemical (IHC) studies. IHC staining was
performed using an ultrasensitive SP-IHC kit (Beijing
Zhongshan Biotechnology, Beijing, China), according to
the manufacturer’s protocol. Briefly, after dewaxing and
rehydration, the antigen was heat-retrieved, endogenous
peroxidase was quenched, and the sample was blocked
with 10% BSA for 30 min at room temperature. The slides
were then immersed in either primary anti-ASS1 (H231;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) or
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polyclonal antibodies overnight at 4°C in a humid cham-
ber, followed by rinsing and incubating with the goat anti-
rabbit secondary antibody kit. The slides were stained with
the 3,3-diaminobenzidine tetrahydrochloride (DAB) kit
(Beijing Zhongshan Biotechnology, Beijing, China) and
were subsequently counterstained with hematoxylin. Two
pathologists assessed the IHC results as described previ-
ously [33]. Finally, the images were examined under a light
microscope (Olympus, Tokyo, Japan). The Ethical Review
Board Committee of the First Affiliated Hospital of Med-
ical College, Xi’an Jiaotong University, China, approved
the experimental protocols and informed consent was
obtained from each patient who contributed tissue
samples.
Reverse transcription-polymerase chain reaction (RT-PCR)
and quantitative-real time RT-PCR
Total RNA from cells was prepared using trizol (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol [34]. Subsequently, the total RNA was reverse-
transcribed into cDNA using a Takara Reverse Tran-
scription Kit (Takara, Dalian, China) according to the
manufacturer’s recommendations. Reverse transcription-
polymerase chain reaction (RT-PCR) was performed as
previously described [35]. For quantitative-real time
(qRT)-PCR reactions, 2 μL of cDNA was mixed with a
reaction mix containing 10 μL of SYBR Green (Takara),
0.8 μL of primers, and water for a total reaction volume of
20 μL. For detecting of ASS1, caspase-3, caspase-9, Bax,
Bcl-2, and survivin at mRNA levels, the following gene
specific primers (Beijing Dingguo Changsheng Biotechnol-


















The number of specific transcripts detected was nor-
malized to the level of GAPDH. Relative quantificationof gene expression (relative amount of target RNA) was
determined using the equation 2(−ΔΔ Ct).
Immunofluorescence
Cells were grown on glass coverslips, fixed with 4% para-
formaldehyde for 10 min at room temperature, and then
incubated with or without (control) the primary anti-
ASS (H231) antibody overnight; the coverslips were then
washed and incubated with the appropriate secondary
antibody conjugated with FITC for 1 h at room temperature.
DAPI was used to stain the nuclei. The coverslips were
mounted onto slides, and the cells were viewed for evaluat-
ing ASS expression using a Leica TCS-SP2 confocal scan-
ning microscope (Leica, Heidelberg, Germany).
Western blot analysis
Total protein from pancreatic cancer tissues or cells was
extracted following lysis in the RIPA lysis buffer (150 mM
NaCl, 50 mM Tris, 1% NP-40, 0.25% sodium deoxycho-
late, and 1 mM EGTA) supplemented with the protease
inhibitor cocktail (Sigma, St, Louis, USA) for 30 min [36].
The resulting debris was removed by centrifugation, and
the supernatant containing the protein lysate was col-
lected. For preparation of the nuclear extracts, cells in the
control and experimental groups were treated for the indi-
cated times, then incubated on ice for 30 min followed by
preparation of the nuclear extracts using a nuclear extract
kit (Pierce) according to the manufacturer's instructions.
The cellular protein content was determined using the
BCA kit (Beyotime Biotechnology, Nantong, China), and
the cell lysates were separated on a 10% SDS-PAGE gel
followed by electro-transfer onto a Millipore PVDF mem-
brane (Billerica, USA). After being blocked with 5% non-
fat milk in TBST, the membranes were incubated with the
respective primary antibodies (pSTAT3 [Tyr705], total-
STAT3, p-ERK1/2 [Thr202/Tyr204], and ERK1/2 [all
from Cell Signaling Technology, Beverly, USA]; p-Akt
[Thr308], total-Akt, total NF-κB p65, caspase-3, caspase-9,
XIAP, c-Jun, p21, p53, β-actin [all from Santa Cruz
Biotechnology]; survivin, p-c-Jun [S73], p-NF-κB p65
[S536], lamin B1 [all from Bioworld]; cyclin D1 [Boster,
Wuhan, China], and ASS1 [Proteintech, Chicago, USA])
at 4 °C overnight, followed by 1:2000 horseradish peroxidase
(HRP)-conjugated secondary antibodies (anti-mouse,
anti-rabbit, anti-goat; Santa Cruz Biotechnology) for 2 h.
Immunoreactive bands were visualized using an enhanced
chemiluminescence kit (Millipore) and photographed
by GeneBox analyzer (SynGene, UK). All analyses were
performed in duplicate.
Cell proliferation assay
Cell proliferation was determined by the MTT uptake
method. Following an overnight culture in a 96-well
plate in 200 μL of suitable medium, cells (5 × 103/well)
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mU/mL), GEM (0–105 nM), or both agents for the indi-
cated time. Then, MTT (5 mg/mL) was added and incu-
bation was continued for 4 h, followed by termination of
the reaction with 150 μL of DMSO per well. Absorb-
ance values were determined at 490 nm on a Dias
automatic microwell plate reader (Dynatech Laboratories,
Chantilly, USA), using DMSO as the blank and cells
cultured in untreated medium as the control group.
The cell viability index was calculated using the formula of
ODsample/ODcontrol × 100%, while inhibition ratio calculated
by formula of (1 – ODsample/ODcontrol) × 100%. Each
experiment was repeated three times.
Colony formation assay
Cells were seeded in a 6-well plate at a density of ap-
proximately 2.0 × 102 per well (2 mL) and allowed to at-
tach for 24 h. Next day, the adherent cells were treated
with ADI (0, or 1.0 mU/mL) or GEM (0 or 100 nM), or
both. When cells were treated with both ADI and GEM,
the cells were first treated with ADI (0, or 1.0 mU/mL)
for 12 h, followed by 100 nM GEM for another 12 h.
After a total of 24 h of treatment, cells were cultured in
DMEM and incubated under optimal culture conditions
for 14 days, fixed with methanol, and stained with 0.1%
crystal violet. Visible colonies were manually counted and
photographed.
Detection of cell apoptosis
Apoptosis was analyzed by three methods: 1) Flow cytom-
etry: Apoptotic cells were analyzed using the Annexin-V-
FITC/PI kit (BD, San Diego, USA) by a FACSCalibur flow
cytometer (BD) according to the manufacturer's instruc-
tions. Briefly, cells (2 × 105/well) were cultured in 6-well
plates in the appropriate medium for 6 h prior to treat-
ment with GEM (100 nM) and/or ADI (1 mU). Following
incubation for the indicated times, cells were trypsinized
and centrifuged, washed with PBS, and stained with
Annexin V and PI in the dark. Samples were analyzed, and
the percentage of apoptotic cells was evaluated. 2) In situ
Annexin V/PI staining: Following the pretreatment as in-
dicated in the flow cytometry, cells were washed with PBS
and stained with 5 μL of anti-Annexin V-FITC and 5 μL
of PI in 500 μL of binding buffer in the dark for 15 min
and then examined using a fluorescence microscope.
3) Hoechst 33258/PI double staining: After treatment
as indicated previously, cells were washed with PBS
and stained with 0.1 mL of Hoechst 33258 (Beyotime
Biotechnology, Nantong, China) and PI for 15 min. Stained
cells were photographed under a fluorescence microscope.
Cell cycle assay
Cells were harvested after treatment at different time
points, and they were resuspended in PBS. The cellswere then fixed in 2 mL of 70% ethanol and incubated
on ice for 30 min, before being washed and treated
with RNase A (100 μg/mL, 5 min) and stained with PI
(50 μg/mL, 15 min). Cellular DNA content was analyzed
in a Coulter Epics XL flow cytometer (Beckman-Coulter,
Villepinte, France).
NF-κB p65 nuclear translocation assay
After the drug treatment, the cells were incubated with
the NF-κB p65 (C-20, Santa Cruz Biotechnology) anti-
body overnight. The subsequent processing was similar
to the immunofluorescence assay. At the final step, the
nuclear translocation of NF-κB p65 was viewed using a
confocal scanning microscope (Leica).
Tumorigenicity in a mouse xenograft model
Six- to eight-week-old male BALB/c athymic mice were
kept under pathogen-free conditions according to institu-
tional guidelines. Each aliquot of approximately 1.0 × 107
PANC-1 pancreatic cancer cells suspended in 100 μL of
PBS containing 20% of Growth Factor Reduced Matrigel
(Becton Dickinson Labware, Flanklin, NJ, USA) was im-
planted subcutaneously into the mouse flank to establish
xenograft tumors. After two weeks, the mice were ran-
domly grouped into 4 groups with six animals in each
group. Mice were intraperitoneally administered either
PBS (vehicle), ADI (2 U/mouse), or GEM (100 mg/kg)
alone or a combination of both ADI and GEM in 100 μL
of PBS every four days. The tumor size was measured
every three days and the tumor volume (in mm3) was cal-
culated using the formula V = 0.4 × D × d2 (V, volume; D,
longitudinal diameter; d, latitudinal diameter). Four weeks
later, the mice were sacrificed and the tumors were
excised and weighed. All animal experiments were
conducted according to a protocol approved by the
Institutional Animal Care and Use Committee of Xi’an
Jiaotong University.
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware (version 16.0, SPSS Inc. Chicago, USA). Experimental
data in vitro and in vivo were expressed as mean ± standard
deviation (SD), and were analyzed by the Student’s un-
paired t-test or one-way ANOVA. For frequency distri-
butions, a χ2 test was used with modification by the
Fisher’s exact test to account for frequency values less
than 5. P < 0.05 was considered statistically significant.
Results
Expression of ASS in pancreatic cancer cells and tissue
The mRNA expression levels of ASS, a key factor that
determines sensitivity to arginine deprivation via ADI,
were measured in several cancer cell lines, including pan-
creatic cancer, breast cancer (low ASS-deficient tumor
Liu et al. BMC Cancer 2014, 14:686 Page 5 of 17
http://www.biomedcentral.com/1471-2407/14/686[37]), and HCC (high ASS-deficient tumor [37,38]) using
qRT-PCR. The MCF-7 breast cancer cell line was used as
a standard control for identifying ASS mRNA expression.
The BxPC-3 (primary pancreatic cancer), SW1990 (spleen
metastatic pancreatic cancer), BT474 (breast cancer), and
HepG2 (HCC) cells expressed high levels of ASS mRNA
and the PANC-1 (primary pancreatic cancer), MIA PaCa-
2 (primary pancreatic cancer), and MDA-MB-231 (breast
cancer) cells expressed low levels of ASS relative to MCF-
7 cells (Figure 1A). The MDA-MB-453 (breast cancer)
and MHCC97-H (HCC) cell lines expressed similar ASS
mRNA levels as MCF-7 cells. Next, the expression level of
ASS protein was evaluated by western blot assay in the
four pancreatic cancer cell lines. The ASS protein expres-
sion pattern was similar to the ASS mRNA expression
pattern in these cells (Figure 1C). Immunofluorescence
analysis verified that ASS protein was located in the cyto-
plasm of BxPC-3 and SW1990 pancreatic cancer cells,
and similar to the qRT-PCR and western blotting results,
PANC-1 and MIA PaCa-2 cells did not express substantial
ASS protein in situ (Figure 1B). Furthermore, we analyzed
the levels of ASS protein in 14 fresh-frozen pancreatic
cancer tissue samples by western blotting and found that
pancreatic cancers expressed low levels of the ASS protein
(7 with ASS expression deficiency) (Figure 1D). Nine of
fourteen tissue specimens were extracted for detection of
ASS mRNA level, and the results show that transcriptional
levels of the ASS gene were similar to its protein expres-
sion in the examined specimens (Figure 1E). Additionally,
the expression of p65 (a subunit of heterodimeric NF-κB
complexes) and caspase-3 (a proapoptotic protein) was
evaluated in 14 pancreatic cancer tissue samples by west-
ern blotting, presenting that there was a constitutional ex-
pression of p65 and caspase-3 proteins in examined
specimens, and high level of caspase-3 expression was as-
sociated with low p65 expression (r = −0.634, P = 0.027;
Figure 1F).
Expression of ASS is associated with unfavorable
biological behaviours in pancreatic cancer
To understand the clinical importance of ASS expres-
sion in primary human pancreatic cancer tissues, we
evaluated ASS expression in human pancreatic cancer
tissues by IHC method. ASS expression was detected in
19 of the 34 (56%) specimens and results from 2 of those
tissues are shown (Figure 1G, i-iv). Reduced ASS expres-
sion correlated with lymph node metastasis, and local
invasion in patients with pancreatic cancer (Table 1). In
addition, the expression of survivin, a member of the in-
hibitor of apoptosis protein (IAP) family, was also de-
tected in the same cancer specimens, and its expression
was found in cytoplasm and/or nucleus in most of the
cancer specimens (25/34, 74%) (Figure 1G, v and vi). By
comparing the expression of ASS and survivin in pancreaticcancer specimens, a positive correlation between reduced
survivin and ASS expression was exhibited (Table 2).
Effect of ADI on the growth, apoptosis, and cell cycle of
pancreatic cancer cells
Next, we examined the cytotoxic effect of ADI on BxPC-
3, SW1990, MIA PaCa-2, and PANC-1 cells by the MTT
assay. Following treatment for one to three days, ADI
significantly decreased the viability of ASS-deficient
PANC-1 and MIA PaCa-2 cells in a dose- and time-
dependent manner, but did not inhibit the proliferation
of ASS-expressing BxPC-3 and SW1990 (Figure 2A).
The 50% inhibitory concentration (IC50) of ADI in
PANC-1 was determined to be 1 mU/mL at 72 h and
was used as the treatment dose in ensuing experi-
ments. Subsequently, primary pancreatic cancer cell
lines PANC-1 and BxPC-3 were used in further cellular
and molecular experiments. The two cell lines treated
with ADI or PBS were analyzed for cell cycle progres-
sion and apoptosis using FACS analysis. The findings
showed that 1 mU/mL of ADI induced PANC-1 cell
cycle arrest at the G1 phase and with a shorter G2/M
phase, but caused scarcely any delay at the respective cell
cycle phase for the BxPC-3 cell line at 24 h (Figure 2B).
Similarly, 1 mU/mL ADI induced significant programmed
cell death in ASS-deficient PANC-1 cells at 24, 48, and 72
h following treatment (Figure 2C), but did not cause apop-
tosis in ASS-positive BxPC-3 cells at 48 h (Figure 2D). In
addition, the cellular morphology of PANC-1 cells was
altered (Figure 2E) and the colony formation ability
was attenuated upon treatment with 1 mU/mL of ADI
(Figure 2F), but these cellular changes were not ob-
served in BxPC-3 cells.
Regulatory role of ADI on the expression of apoptosis-related
proteins, cell cycle protein cyclin D1, and phosphorylation
of STAT3, AKT, and NF-κB p65
To explore the precise mechanisms of ADI-induced
apoptosis in pancreatic cancer cells, we studied several
apoptosis-related proteins using western blotting. Our
findings showed that, after 12 h treatment, ADI signifi-
cantly downregulated the expression of two IAP-family
antiapoptotic proteins, namely X-linked IAP (XIAP) and
survivin (Figure 3A), and simultaneously upregulated the
expression of caspase-3 and caspase-9 that are respon-
sible for the release of mitochondrial proapoptotic pro-
teins (Figure 3B) in PANC-1 cells; however, the same
concentration of ADI treatment did not alter the expres-
sion of these apoptosis-related proteins in BxPC-3 cells
(Figure 3D). Next, we found considerable accumulation
of p53 protein in the p53-mutant PANC-1 (Figure 3C)
and BxPC-3 (Figure 3E) cells, but p53 expression was
not significantly altered after ADI treatment in either
cell line, and no significant change in p21 protein (a p53
Figure 1 The expression of ASS mRNA and protein in pancreatic cancer cell lines and human tissues. A, The level of ASS mRNA in human
pancreatic cancer cell lines MIA PaCa-2, PANC-1, BxPC-3, and SW1990, breast cancer (low ASS-deficient tumor [37]) cell lines MDA-MB-453, BT474,
MDA-MB-231, and MCF-7, and hepatocellular carcinoma (high ASS-deficient tumor [37,38]) cell lines HepG2 and MHCC97-H were examined by
qRT-PCR assay. B, Cytoplasmic localization of ASS protein in MIA PaCa-2, PANC-1, SW1990, and BxPC-3 cells was verified by immunofluorescence
assay. C, The expression level of ASS protein was evaluated by western blot assay in the pancreatic cancer cell lines. D, The expression of ASS protein
in 14 pancreatic cancer tissues was detected by western blotting (H1 is a normal hepatic tissue obtained from a hepatorrhexis patient), yielding that the
deficiency of ASS protein expression was up to 50% (7/14). E, Relative mRNA levels of ASS in 9 pancreatic cancer tissues were analyzed by RT-PCR (H1 as
depicted Figure 1D), reporting similar ASS deficiency as protein level in examined specimens. F, The relative expression levels of the p65 subunit of NF-κB
and caspase-3 proteins in 14 pancreatic cancer tissues were detected by western blotting. G, The expression of ASS or survivin was determined in
pancreatic cancer tissue samples using immunohistochemistry (IHC). Images i and ii show ASS expression in a tissue sample obtained from
a grade 3 pancreatic adenocarcinoma patient with chronic pancreatitis and without metastasis to the lymph nodes or other organs, while iii
and iv show ASS expression in a tissue sample obtained from a grade 2 invasive adenocarcinoma characterized by lymphatic and liver metastases.
Images in v and vi show survivin expression in a tissue sample from a grade 2 invasive adenocarcinoma with tumor extension and invasion
into peripancreatic fat and multiple fibrous adhesions.
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Table 1 Relation between clinical and histological




Median age (range) years 63 (47–78) 68 (44–83)
Sex (male:female) 11:8 10:6
Histological grade
I 3 (9%) 2 (6%)
II 12 (35%) 9 (26%)
III 4 (12%) 4 (12%)
Tumor size (cm)
≤ 3 6 (18%) 3 (9%)
> 3–≤ 6 10 (29%) 11 (32%)
>6 3 (9%) 1 (3%)
Pathologic stage
I 3 (9%) 1 (3%)
II 11 (32%) 8 (24%)
III 2 (6%) 2 (6%)
IV 3 (9%) 4 (12%)
Lymph node metastasis
Positive 9 (26%) 13 (35%)
Negative 10 (29%) 2 (9%)*
Local invasion
Positive 7 (24%) 12 (29%)
Negative 12 (32%) 3 (15%)*
*P < 0.05.
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nificant cellular and molecular changes in ASS-positive
BxPC-3 pancreatic cancer cell after ADI treatment, we
focused on the relevant studies in the ASS-negative
PANC-1 cell line. After 0 to 24 h treatment with ADI,
caspase-3 activation increased progressively in a time-
dependent fashion, while the expression of cyclin D1
was reduced in PANC-1 cells (Figure 4A). Further-
more, we tested the phosphorylation levels of p65 at
serine 536 (p-p65 [Ser536]), shown to play a critical
role in the activation of the NF-κB pathway [39,40],
in PANC-1 cells treated with ADI at several time points.
We discovered that p-p65 (Ser536) decreased in a time-




Survivin Positive 11 (41%) 14 (41%)
Negative 8 (15%) 1 (3%)*
*P < 0.05.To understand whether ADI treatment blocked the phos-
phorylation of NF-κB p65 in PANC-1 cells via altering
survival signaling, we detected the levels of Akt, p-Akt,
ERK1/2, p-ERK1/2, STAT3, and p-STAT3. The results
showed that ADI treatment for 8 h inhibited phosphoryl-
ation of STAT3 and Akt, but not ERK1/2 (Figure 4C).
Effect of ADI on GEM-induced cytotoxicity in pancreatic
cancer cells
To evaluate the antiproliferative activity of ADI that po-
tentiated GEM treatment, the MTT assay was initially
conducted. The IC50 of GEM that inhibited the prolifer-
ation of BxPC-3 (Additional file 2: Figure S2A) and
PANC-1 (Additional file 2: Figure S2B) cells was esti-
mated by the MTT assay to be approximately 30 nM
and 100 nM at 72 h, respectively; this concentration was
then used in the subsequent experiments. GEM in com-
bined with 6 h ADI pretreatment significantly inhibited
the proliferation of PANC-1 cells compared to ADI or
GEM alone (Additional file 2: Figure S2D), but this ef-
fect was not observed in BxPC-3 cells (Additional file 2:
Figure S2C). Furthermore, by using in situ fluores-
cence microscopy visualization (Figure 5A) and FACS
(Figure 5B), it was revealed that ADI pretreatment for
6 h promoted GEM-induced PANC-1 cell apoptosis by
24 h. We found that the apoptotic cells in situ readily
stained with Annexin V-FITC/PI (green and red fluor-
escence) as well as with Hoechst and PI (blue and red
fluorescence) (Figure 5A). Additionally, the GEM me-
diated S phase-arrest was enhanced in the case of pre-
treatment with ADI for 6 h (Figure 5C). We conducted
a colony formation assay to test the colony-formation
potential of individual PANC-1 cells; the results showed
that GEM in combination with ADI pretreatment for 6 h
reduced the colony numbers of PANC-1 cells compared
to GEM or ADI alone (Figure 5D).
Effect of ADI on the transcription levels of apoptosis-related
genes
To further understand the molecular changes associated
with ADI-mediated potentiation of GEM-induced apop-
tosis in PANC-1 cells, we examined the mRNA levels of
Bax, Bcl-2, caspase-3, and -9, and survivin in the cells by
qRT-PCR. As shown in Figure 6A, both ADI and GEM
upregulated Bax, caspase-3 and -9 mRNA levels; GEM
induced the mRNA level of the antiapoptotic gene Bcl-2;
while ADI not only decreased the expression of Bcl-2
but also inhibited the induction of Bcl-2 transcription by
GEM (with ADI pretreatment for 6 h). Additionally,
ADI downregulated survivin mRNA, while GEM had
limited impact on survivin gene transcription; however,
the combination of ADI pretreatment for 6 h with GEM
resulted in even greater inhibition of survivin expression
than ADI alone.
Figure 2 (See legend on next page.)
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(See figure on previous page.)
Figure 2 The effect of ADI on the cell proliferation, apoptosis, cell cycle, and colony formation of pancreatic cancer cells. A, The
proliferation-inhibitory effect of ADI on BxPC-3, PANC-1, SW1990, and MIA PaCa-2 cells was measured by the MTT assay. *, P < 0.05 as compared
with the control group (0 mU/mL ADI). B, Cell cycle progression of primary pancreatic cancer cell lines BxPC-3 and PANC-1 after treatment with or
without ADI was analyzed by FACS. *, P < 0.05 as compared with the control group (0 mU ADI/mL); NS, not significant. C, The percentage of apoptotic
PANC-1 cells treated with ADI was calculated by FACS. D, The percentage of apoptotic BxPC-3 cells treated by ADI for 48 h was calculated by FACS.
E, ADI (1 mU/mL) intervention altered cell morphology of PANC-1 cells but not BxPC-3 cells. F, The colony forming ability of PANC-1 cells was altered
by ADI intervention, while BxPC-3 colony formation was not changed. *, P < 0.05 as compared with the control group (0 mU ADI/mL).
Figure 3 The effect of ADI on apoptosis-related proteins and cell cycle protein cyclin D1 in pancreatic cancer cells. A and B, Treatment
with ADI (1 mU/mL) regulates the levels of antiapoptotic proteins XIAP and survivin, and pro-apoptotic proteins caspase-3 and caspase-9 in
PANC-1 cells. *, P < 0.05 as compared with the control group (0 mU/mL ADI); NS, not significant. C, ADI does not alter the expression level of p53
and p21 proteins in PANC-1 cells, as compared with the control group. D and E, ADI does not alter the expression level of p53 and p21 proteins
in BxPC-3 cells, as compared with the control group.
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Figure 4 The effect of ADI on caspase-3 and cyclin D1, and the phosphorylation of NF-κB p65, STAT3, Akt, and ERK1/2 in ASS-deficient
PANC-1 cells. A, ADI (1 mU/mL) up-regulates caspase-3 protein and decreases cell cycle protein cyclin D1 in a time-dependent manner in
PANC-1 cells. *, P < 0.05 as compared with the treatment at 0 h; NS, not significant. B, ADI treatment (1 mU/mL for 0–24 h) of PANC-1 cells
resulted in reduced phosphorylation of the NF-κB p65 subunit at Ser536. *, P < 0.05 as compared with the treatment group at 0 h; NS, not
significant. C, The effect of ADI (1 mU/mL) on the phosphorylation of cell survival- associated proteins STAT3, Akt, and ERK1/2. *, P < 0.05 as
compared with the control group; NS, not significant.
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translocation of NF-κB p65 protein
We next determined whether ADI potentiated the GEM-
induced apoptosis of PANC-1 cells by blocking activation
of the NF-κB pathway. We found that ADI pretreatment
for 6 h downregulated the nuclear expression of p65 and
inhibited p65 induction by GEM (Figure 6B). Next, we
studied whether ADI inhibited the GEM-induced p65 nu-
clear translocation in PANC-1 cells using in situ immuno-
fluorescence microscopy. As shown in Figure 6C, p65 was
located in the cytoplasm in the control group and in the
ADI-treated group, while a significant amount of p65 was
visible in the nucleus as green fluorescent spots in the
GEM-treated group. However, when PANC-1 cells treated
with both GEM and the pretreatment ADI for 6 h, the
green fluorescent nuclear spots of p65 disappeared, indi-
cating that ADI can block the nuclear translocation of the
NF-κB p65 subunit. To evaluate whether ADI regulates
GEM-induced activation of NF-κB pathway by inhibiting
p65 phosphorylation, we examined the ratio of p-p65
(Ser536) to total p65 in nuclear and cytoplasmic extracts.
Our analysis of the nuclear proteins showed that ADI sig-
nificantly decreased p-p65 expression levels, while GEM
did not. Additionally, ADI pretreatment reduced p-p65
levels in combination with GEM. In the cytoplasmic ex-
tracts, GEM significantly increased p-p65 expression
which was unaffected by ADI alone, but significantly
reduced in ADI pretreatment combined with GEM
(Figure 6D). Together, these data provide evidence thatADI can suppress NF-κB pathway activation. Furthermore,
GEM alone induced c-Jun phosphorylation at Ser73, but
ADI alone or together with GEM did not. However, ADI
pretreatment for 6 h could decrease the p-c-Jun induction
by GEM alone, indicating that ADI could maintain c-Jun
phosphorylation at the baseline level (Figure 6E). Finally,
we validated the expression of survivin protein in nuclear
extracts and found results similar to that for mRNA ex-
pression inhibited by ADI treatment; however, GEM in-
creased the expression of nuclear survivin (Figure 6F).
ADI blocks NF-κB p65 phosphorylation (serine 536) via
inactivating PI3K/Akt survival signal pathway
To understanding whether ADI down-regulated the
phosphorylation of NF-κB p65 by blocking activation
of the PI3K/Akt survival signal pathway, we evaluated
the expression of several important proteins in this sig-
naling pathway in pancreatic cancer cells treated with
ADI in combination with the PI3K inhibitor LY294002
treatment for 20 min. The results showed that ADI
combined with LY294002 at 20 μM significantly down-
regulated the level of p-Akt (Thr308) and p-p65 (Ser536),
but not p-ERK1/2 (Thr202/Tyr204) in ASS-deficient
PANC-1 cells, as compared to ADI treatment alone
(P < 0.05) (Figure 7A); however, the combined treatment
of ADI and LY294002 did not change the expression of
relevant proteins of the PI3K/Akt and NF-κB p65 signal-
ing pathways as compared with ADI treatment alone, in
ASS-positive BxPC-3 pancreatic cancer cells (Figure 7B).
Figure 5 The impact of ADI combined with GEM on PANC-1 cell apoptosis, cell cycle arrest, and inhibition of colony formation. A,
Apoptosis in PANC-1 cells at the 24 hour time point in the control group, ADI alone, GEM alone, or both ADI and GEM groups was visualized by
in situ fluorescence microscopy using the indicated dyes (Annexin V-FITC/PI or Hoechst 33258/PI). B, The percentages of apoptotic PANC-1 cells
treated with vehicle, ADI alone, GEM alone, or both drugs were estimated by FACS analysis following staining with Annexin V-FITC/PI. C, Cell cycle
progression of PANC-1 cells following treatment with ADI or GEM alone or in combination was analyzed by single staining with PI. *, P < 0.05, as
compared with the control group or indicated groups. D, Proliferative activity of PANC-1 cells treated by GEM following ADI was viewed by the
single cell colony formation assay.
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of PANC-1 pancreatic cancer cells in vivo
Based on our findings that ADI blocks NF-κB signaling,
leading to enhance GEM-induced apoptosis of PANC-1
cells in vitro, we thus sought that it would be interesting
to determine if ADI enhanced the antitumor effect of
GEM in vivo. For these studies, PANC-1 cells were sub-
cutaneouly implanted into nude mice to generate a
xenograft. When the xenograft tumors had grown to ap-
proximately 50 mm3, the mice (n = 6) were treated with
PBS (vehicle), ADI (2 U/mouse), GEM (100 mg/kg), or
both ADI and GEM. The tumors regressed during the
treatment period in all groups except the vehicle group
(Figure 8A and B). From days 15–24, treatment with
both ADI and GEM markedly regressed tumor growth
when compared to GEM or ADI alone, and minimaltumors were observed in the combination group at re-
section (Figure 8B).
Discussion
In this report, we show that reduced ASS expression is
correlated with unfavorable tumor behaviors in patients
with pancreatic cancer, and arginine deprivation by ADI
can effectively induce programmed cell death in PANC-
1 cells with undetectable ASS expression, and also
sensitize pancreatic cancer cells to GEM, a first-line
chemotherapy in pancreatic cancer. In addition, we dem-
onstrate the mechanism by which ADI augments the
sensitivity of ASS-deficient pancreatic cancer cells to
GEM treatment. Our findings show that ADI alone re-
sults in down-regulation of IAP family member survivin
and XIAP, and induces caspase-dependent apoptosis.
Figure 6 The molecular changes on ADI treatment enhanced the sensitivity of PANC-1 cells to GEM. A, The mRNA levels of Bax, Bcl-2,
caspase-3, and -9, and survivin were examined in four experimental groups of PANC-1 cells by qRT-PCR analyses. *, P < 0.05, as compared with
the control group or indicated groups; NS, not significant. B, The ratio of nuclear p65 to cytoplasmic p65 protein expression, and the relative expression
of p65 protein in nuclear extracts were tested in control, ADI, GEM, or ADI + GEM-treated PANC-1 cells. *, P< 0.05, as compared with the control group;
#, P< 0.05, as compared with the indicated groups; NS, not significant. C, Inhibition of GEM-induced p65 nuclear translocation by ADI in PANC-1 cells
was visualized by in situ immunofluorescence microscopy. D, The ratio of p-p65 (Ser536) to total (t)-p65 protein expression in nuclear and
cytoplasmic extracts was tested in PANC-1 cells treated with experimental treatments. *, P < 0.05, as compared with the control group; #, P < 0.05,
as compared with the indicated groups; NS, not significant. E, The phosphorylation levels of c-Jun protein (Ser73) in nuclear extracts of PANC-1 cells
treated with various agents were detected by western blotting. *, P < 0.05, as compared with the control group; #, P < 0.05, as compared with the
indicated groups; NS, not significant. F, The levels of IAP survivin protein in nuclear extracts from treated-PANC-1 cells were detected by
western blotting. *, P < 0.05, as compared with the control group; #, P < 0.05, as compared with the indicated groups.
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vival signaling to exhibit antitumor effects. By blocking
PI3K/Akt signaling and suppressing NF-κB activation via
inhibition of the nuclear translocation and phosphoryl-
ation (serine 536) of nuclear NF-κB p65, ADI displays a
highly significant synergism in anticancer activities against
pancreatic cancer cells deficient in ASS expression in
combination with GEM (Figure 8C). Thus, the present
study offers a new treatment strategy for pancreatic cancer
involving arginine depletion.
ADI has been reported to have antitumor activity, it is anti-
angiogenic, and it synergizes to promote dexamethasone-
induced cytotoxicity [10,14,15,41-43]. As described in
previous studies cancer cells are sensitive to the anti-
proliferative activity of ADI arginine deprivation, whichcorrelates with the endogenous arginine metabolic en-
zyme, ASS [10,13,15]. Here, we found that the majority of
human pancreatic cancer specimens have a low expression
of ASS, and reduced ASS expression was associated with
unfavorable histopathological characteristics of pancreatic
cancer. In four of the pancreatic cancer cell lines that were
examined, the ASS mRNA levels by qRT-PCR assay were
similar as previously reported, but expression in SW1990
was not detected (Figure 1A); as a pilot study on ADI
apply to treatment for pancreatic cancer, this work dem-
onstrated the effect of PEG-ADI on cell growth inhibition
and apoptosis induction in MIA PaCa-2 pancreatic cancer
cells [15]. However, the study was worthwhile to under-
stand the precise mechanism of ADI-induced pancreatic
cancer cell growth inhibition and apoptosis induction.
Figure 7 The effect of ADI in combination with PI3K inhibitor LY294002 on PI3K/Akt survival signal pathway. Protein expression levels of
phosphorylated and total levels of Akt, p65, Erk1/2 along with PI3KCA and B-actin were detected in A, PANC-1 cells and B, BxPC-3 cells treated
with or without ADI and LY294002. The combined treatment significantly reduced p-Akt and p-p65 expression in PANC-1, but not BxPC-3 cells, as
shown in the densitometry graphs. *, P < 0.05, as compared with the control group; #, P < 0.05, as compared with the indicated groups; NS,
not significant.
Liu et al. BMC Cancer 2014, 14:686 Page 13 of 17
http://www.biomedcentral.com/1471-2407/14/686The present study contributed to our understanding of
some of the signaling mechanisms regulated by ADI in
ASS-deficient PANC-1 cells. Naturally, our results are
likely to be generally applicable to other pancreatic cancer
cells that lack ASS expression, other than the cell lines
used in this study.
A number of studies demonstrate that GEM treatment
can induce NF-κB signal activation [23,44]. NF-κB acti-
vation is involved in the inhibition of apoptosis, induc-
tion of mitogenic gene products such as cyclin D1,increased expression of proangiogenic factors, and regula-
tion of gene products that promote migration and inva-
sion of pancreatic cancer cells, which together contribute
to the chemoresistance of pancreatic cancer [45-49]. By
arginine depletion, ADI causes metabolic stress in arginine
auxotrophic cells, which could compliment conventional
GEM-based chemotherapies that are largely based on gen-
otoxic stress. In our report, fourteen pancreatic cancer
specimens had varying expression levels of NF-κB p65
and showed an inverse correlation with the expression of
Figure 8 ADI promoted chemosensitivity to GEM in vivo. A, The effect of ADI and/or GEM treatment on the growth of PANC-1 tumors in
BALB/c athymic mice are shown. All treatment groups resulted in significant reduction in tumor volume after 24 days relative to the control
group; however, the treatment with both ADI and GEM resulted in the greatest growth inhibition overall. Further, ADI + GEM significantly inhibited
tumor growth when compared to GEM alone during days 15 to day 24. *, P < 0.05, **, P< 0.01, ***, P< 0.001 as compared with vehicle group. #, P < 0.05,
as compared with GEM or ADI alone group. B, Representative images of pancreatic tumors obtained from the mice treated with control, ADI, GEM, or
ADI + GEM are shown. The tumors were collected at the end of the 24-day treatment period. The combined treatment of ADI + GEM resulted in the
greatest reduction of tumor growth. C, Proposed model for how ADI sensitizes pancreatic cancer cells to GEM and results in cell death. ADI deprives cells
of arginine which leads to inhibition of STAT and PI3K/Akt pathways. As a consequence, NF-κB activity and nuclear translocation are reduced leading to
decreased synthesis of pro-survival proteins and increased synthesis of pro-death proteins. These events sensitize pancreatic cancer cells to chemotherapy
(GEM) resulting in cell death.
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http://www.biomedcentral.com/1471-2407/14/686caspase-3. Our in vitro studies showed that ADI upregu-
lates many proapoptotic factors, such as Bax, caspase-3
and −9, and simultaneously downregulates antiapoptotic
gene products, Bcl-2, XIAP, and survivin, but not p53 and
p21, indicating that ADI promoted apoptosis in PANC-1
cells in part via caspase activation and suppression of
IAPs. ADI treatment blocked the phosphorylation of
NF-κB p65 subunit. With the combination therapy of ADI
and GEM, we found that ADI obstructs the GEM-
mediated NF-κB p65 protein translocation into the nu-
cleus where NF-κB binds with various genes and activates
their transcription [50-52]. By suppressing p65 subunit
nuclear translocation and phosphorylation at Ser536, the
two NF-κB activation pathways [25,26,39,40], ADI reduces
chemoresistance, producing a synergism on with GEM-
induced programmed cell death in PANC-1 pancreatic
cancer cells. Moreover, a preliminary animal experiment
also validated the synergism of ADI with the antitumor ef-
fect of GEM in vivo. Our study provides the first data sug-
gesting that ADI enhances the chemosensitivity to GEM
by suppression of NF-κB p65 nuclear translocation and
phosphorylation of nuclear p65 subunit, and thus, the
work described here offers a new treatment option for
pancreatic cancer.
Multiple signals regulate or synergize with NF-κB path-
way activation, such as PI3K/Akt [25,26], STAT3 [45], and
MAPK/ERK1/2 [53,54]. We explored whether ADI alters
the phosphorylation levels of cell survival-associated sig-
naling pathway proteins, including Akt, STAT3, and
ERK1/2. Our findings revealed that ADI reduced p-Akt
and p-STAT3 levels, but not p-ERK1/2. Based on our ex-
periments with ADI treatment alone, we postulate that
ADI may obstruct nuclear translocation of NF-κB p65
subunit and downregulate nuclear p65 phosphorylation
at Ser536 via suppression of PI3K/Akt signaling under
metabolic stress by arginine depletion. Indeed, the mo-
lecular studies in pancreatic cancer cells verified this
hypothesis.
Conclusion
Although GEM-based chemotherapies are currently the
standard of care for the treatment of advanced pancreatic
cancer, its efficacy is limited because pancreatic cancer
cells are often resistant to GEM through a mechanism
that involves NF-κB activation. In this context, our find-
ings suggest that reduced ASS expression predicts un-
favorable tumor behaviours, while in ASS-deficient
PANC-1 cells, ADI enhances their chemosensitivity to
GEM-induced apoptosis. The mechanism by which ADI
synergized with GEM involved inhibiting PI3K/Akt/NF-κB
signaling, as evidenced by NF-κB pathway inactiva-
tion via the suppression of nuclear translocation and
phosphorylation of the p65 subunit at Ser536. Therefore,
the combination of ADI and GEM is advantageous becauseof their complementary action, and will offer a novel treat-
ment strategy for pancreatic cancer.
Additional files
Additional file 1: Figure S1. The proteinogram of heat-denatured ADI
protein from M. arginini. The ADI gene was cloned from M. arginini genomic
DNA and recombinant ADI was overexpressed and purified as previously
described [31]. The molecular weight of purified ADI was observed to
be 46 kDa.
Additional file 2: Figure S2. ADI sensitizes pancreatic cancer cells to
GEM-induced growth inhibition. A, GEM inhibited the proliferation of
BxPC-3 cells at continuous concentrations estimated by the MTT growth
assay. B, GEM inhibited the proliferation of PANC-1 cell growth estimated
by the MTT growth assay. C, ADI in combination with GEM did not
increase the inhibition ratio of proliferation in BxPC-3 cells more than that of
treatment with GEM alone. D, ADI in combination with GEM significantly
increased the inhibition ratio of proliferation in PANC-1 cells compared to
treatment with ADI or GEM alone. * P < 0.05, ** P < 0.01, *** P < 0.001 as
compared with control group or indicated groups.
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